Table 1.
Patient characteristics and treatment
| Total (N = 64) | |
|---|---|
| Sex | |
| Female | 14 (21.9) |
| Male | 50 (78.1) |
| Age, years | |
| Mean (standard deviation) | 64.4 (9.7) |
| Median (min, max) | 65.5 (37, 84) |
| < 65 | 31 (48.4) |
| ≥ 65 | 33 (51.6) |
| Previous cancer treatment regimensa | |
| Median (min, max) | 4 (2, 11) |
| 2 | 17 (26.6) |
| 3 | 10 (15.6) |
| 4 | 15 (23.4) |
| 5 | 15 (23.4) |
| ≥ 6 | 7 (10.9) |
| Previous treatment | |
| Therapy containing trastuzumab | 64 (100.0) |
| Therapy containing taxanes | 59 (92.2) |
| Therapy containing ramucirumab | 56 (87.5) |
| Immune checkpoint inhibitor | 34 (53.1) |
| Nivolumab | 32 (50.0) |
| Irinotecan or other topoisomerase I inhibitor | 21 (32.8) |
| Trifluridine and tipiracil hydrochloride | 20 (31.3) |
| HER2 baseline status (before trastuzumab deruxtecan treatment) | |
| IHC 3 + | 47 (73.4) |
| IHC 2 + with ISH-positive | 17 (26.6) |
| Primary tumor site | |
| Stomach | 52 (81.3) |
| GEJ | 12 (18.8) |
Data are shown as n (%) unless otherwise stated
GEJ gastroesophageal junction; HER2 human epidermal growth factor receptor 2; IHC immunohistochemistry; ISH in situ hybridization
aExcluding radiotherapy and surgery; the expanded-access study protocol mandated that at least two prior regimens were necessary for inclusion